(Q37928996)

25 August 2017

1 reference

title

Influenza: status and prospects for its prevention, therapy, and control (English)

1 reference

25 August 2017

Heilman C

1

1 reference

25 August 2017

La Montagne JR

series ordinal

2

1 reference

25 August 2017

publication date

1 June 1990

1 reference

Pediatric Clinics of North America

25 August 2017

published in

1 reference

25 August 2017

volume

37

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

669-688

1 reference

Emergence of amantadine-resistant H5N2 avian influenza virus during a simulated layer flock treatment program.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold-adapted vaccine recombinant in which vaccine-associated illness occurred in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Structure of the catalytic and antigenic sites in influenza virus neuraminidase

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Tick-borne viruses structurally similar to Orthomyxoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Pilot Studies on Recombinant Cold-Adapted Live Type A and B Influenza Virus Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Prophylaxis and treatment of influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Serious morbidity and mortality associated with influenza epidemics

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Molecular basis of resistance of influenza A viruses to amantadine.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

The receptor-destroying enzyme of influenza C virus is neuraminate-O-acetylesterase.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Public Health Service study of Reye's syndrome and medications. Report of the main study

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Comparison of live and inactivated influenza vaccine in high risk children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

The gene structure and replication of influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Studies on the origin of pandemic influenza. 3. Evidence implicating duck and equine influenza viruses as possible progenitors of the Hong Kong strain of human influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Expression of antisense RNA fails to inhibit influenza virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Amplification, expression, and packaging of foreign gene by influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Evaluation of an attenuated, cold-recombinant influenza B virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Cell-surface expression of influenza virus haemagglutinin in insect cells using a baculovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Influenza vaccination with adjuvant RU41740 in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Evidence for host-cell selection of influenza virus antigenic variants

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

A Virus Obtained from Influenza Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Enhancement of humoral immune responses against viral vaccines by a non-pyrogenic 6-O-acylmuramyldipeptide and synthetic low toxicity analogues of lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines--I

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

Cold-adapted recombinant influenza A virus vaccines in seronegative young children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2936910-3

7 January 2021

10.1016/S0031-3955(16)36910-3

Identifiers

DOI

0 references

1 reference